Purification and characterization of a novel growth factor from human breast cancer cells

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

We have purified and characterized a novel 30-kDa glycoprotein (gp30) with TGFα-like properties secreted from the estrogen receptor negative breast cancer cell line MDA-MB-231. This factor was immunoprecipitated by an anti-TGFα polyclonal antibody and also had TGFα-like biological activity, as assayed by EGF radioreceptor assay and anchorage-independent assays. In addition, the novel growth factor stimulated phosphorylation of the EGF receptor and erbB-2 receptor. However, the novel growth factor, unlike EGF and TGFα, bound to heparin-Sepharose. Purification of gp30 was obtained to apparent homogeneity by heparin affinity chromatography and subsequent reversed-phase chromatography. Tunicamycin treatment in vivo or N-glycanase deglycosylation in vitro revealed a putative precursor of approximately 22 kDa molecular mass in contrast to the "normal" 16-kDa precursor species for TGFa. In vitro translation of total mRNA from MDA-MB-231 cells confirmed the size of the putative precursor. Biochemical characterization of gp30 was begun by V8 protease digestion of the deglycosylated polypeptide and the translated products. Peptide mapping of V8-digested, immunoprecipitated material suggests that the amino acid sequence of this unique protein is distinct from mature TGFα and not the result of a posttranslational modification of the precursor. We conclude that this TGFα-like (gp30) polypeptide is a novel growth factor with agonistic activity for both EGF and erbB-2 receptors.

Original languageEnglish (US)
Pages (from-to)7330-7340
Number of pages11
JournalBiochemistry
Volume31
Issue number32
StatePublished - 1992
Externally publishedYes

Fingerprint

Epidermal Growth Factor
ErbB-2 Receptor
Purification
Intercellular Signaling Peptides and Proteins
Cells
Breast Neoplasms
Peptides
Assays
Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase
Affinity chromatography
Tunicamycin
Radioligand Assay
Phosphorylation
Peptide Mapping
Molecular mass
Protein Biosynthesis
Reverse-Phase Chromatography
Post Translational Protein Processing
Chromatography
Bioactivity

ASJC Scopus subject areas

  • Biochemistry

Cite this

Purification and characterization of a novel growth factor from human breast cancer cells. / Lupu, Ruth.

In: Biochemistry, Vol. 31, No. 32, 1992, p. 7330-7340.

Research output: Contribution to journalArticle

@article{fc9cbe01fa5e489b9b94f97d94561b83,
title = "Purification and characterization of a novel growth factor from human breast cancer cells",
abstract = "We have purified and characterized a novel 30-kDa glycoprotein (gp30) with TGFα-like properties secreted from the estrogen receptor negative breast cancer cell line MDA-MB-231. This factor was immunoprecipitated by an anti-TGFα polyclonal antibody and also had TGFα-like biological activity, as assayed by EGF radioreceptor assay and anchorage-independent assays. In addition, the novel growth factor stimulated phosphorylation of the EGF receptor and erbB-2 receptor. However, the novel growth factor, unlike EGF and TGFα, bound to heparin-Sepharose. Purification of gp30 was obtained to apparent homogeneity by heparin affinity chromatography and subsequent reversed-phase chromatography. Tunicamycin treatment in vivo or N-glycanase deglycosylation in vitro revealed a putative precursor of approximately 22 kDa molecular mass in contrast to the {"}normal{"} 16-kDa precursor species for TGFa. In vitro translation of total mRNA from MDA-MB-231 cells confirmed the size of the putative precursor. Biochemical characterization of gp30 was begun by V8 protease digestion of the deglycosylated polypeptide and the translated products. Peptide mapping of V8-digested, immunoprecipitated material suggests that the amino acid sequence of this unique protein is distinct from mature TGFα and not the result of a posttranslational modification of the precursor. We conclude that this TGFα-like (gp30) polypeptide is a novel growth factor with agonistic activity for both EGF and erbB-2 receptors.",
author = "Ruth Lupu",
year = "1992",
language = "English (US)",
volume = "31",
pages = "7330--7340",
journal = "Biochemistry",
issn = "0006-2960",
publisher = "American Chemical Society",
number = "32",

}

TY - JOUR

T1 - Purification and characterization of a novel growth factor from human breast cancer cells

AU - Lupu, Ruth

PY - 1992

Y1 - 1992

N2 - We have purified and characterized a novel 30-kDa glycoprotein (gp30) with TGFα-like properties secreted from the estrogen receptor negative breast cancer cell line MDA-MB-231. This factor was immunoprecipitated by an anti-TGFα polyclonal antibody and also had TGFα-like biological activity, as assayed by EGF radioreceptor assay and anchorage-independent assays. In addition, the novel growth factor stimulated phosphorylation of the EGF receptor and erbB-2 receptor. However, the novel growth factor, unlike EGF and TGFα, bound to heparin-Sepharose. Purification of gp30 was obtained to apparent homogeneity by heparin affinity chromatography and subsequent reversed-phase chromatography. Tunicamycin treatment in vivo or N-glycanase deglycosylation in vitro revealed a putative precursor of approximately 22 kDa molecular mass in contrast to the "normal" 16-kDa precursor species for TGFa. In vitro translation of total mRNA from MDA-MB-231 cells confirmed the size of the putative precursor. Biochemical characterization of gp30 was begun by V8 protease digestion of the deglycosylated polypeptide and the translated products. Peptide mapping of V8-digested, immunoprecipitated material suggests that the amino acid sequence of this unique protein is distinct from mature TGFα and not the result of a posttranslational modification of the precursor. We conclude that this TGFα-like (gp30) polypeptide is a novel growth factor with agonistic activity for both EGF and erbB-2 receptors.

AB - We have purified and characterized a novel 30-kDa glycoprotein (gp30) with TGFα-like properties secreted from the estrogen receptor negative breast cancer cell line MDA-MB-231. This factor was immunoprecipitated by an anti-TGFα polyclonal antibody and also had TGFα-like biological activity, as assayed by EGF radioreceptor assay and anchorage-independent assays. In addition, the novel growth factor stimulated phosphorylation of the EGF receptor and erbB-2 receptor. However, the novel growth factor, unlike EGF and TGFα, bound to heparin-Sepharose. Purification of gp30 was obtained to apparent homogeneity by heparin affinity chromatography and subsequent reversed-phase chromatography. Tunicamycin treatment in vivo or N-glycanase deglycosylation in vitro revealed a putative precursor of approximately 22 kDa molecular mass in contrast to the "normal" 16-kDa precursor species for TGFa. In vitro translation of total mRNA from MDA-MB-231 cells confirmed the size of the putative precursor. Biochemical characterization of gp30 was begun by V8 protease digestion of the deglycosylated polypeptide and the translated products. Peptide mapping of V8-digested, immunoprecipitated material suggests that the amino acid sequence of this unique protein is distinct from mature TGFα and not the result of a posttranslational modification of the precursor. We conclude that this TGFα-like (gp30) polypeptide is a novel growth factor with agonistic activity for both EGF and erbB-2 receptors.

UR - http://www.scopus.com/inward/record.url?scp=0026658555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026658555&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 7330

EP - 7340

JO - Biochemistry

JF - Biochemistry

SN - 0006-2960

IS - 32

ER -